Artelo Biosciences Inc.
ARTL
Corporate Overview We incorporated in the State of Nevada on May 2, 2011, and are presently based in the County of San Diego, California. We are a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the ECS ), a network of receptors and neurotransmitters t…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$11M
▼ -31.1% YoY
Op. Margin
–
ROIC
-159.25%
▼ -386.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$12M
▼ -4.3% YoY
Op. Cash Flow (TTM)
-$12M
▼ -2.0% YoY
Net Debt
$36K
Cash & Equiv.
$4K
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with ARTL
Artelo Biosciences (ARTL) in two numbers
Questions about Artelo Biosciences
Does Artelo Biosciences (ARTL) pay a dividend?
No. Artelo Biosciences (ARTL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 11 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ARTL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ARTL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.